Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARAVAGGIO: apixaban versus dalteparin for cancer-associated venous thromboembolism
MOH_2017-08-20_000747Phase 3Not yet recruiting
- Sponsor
- Fondazione FADOI
- Start
- Jan 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) comparing Apixaban group with Dalteparin group (2 arms). Planned start Jan 2017; status: not yet recruiting.
02
Drugs
apixabandalteparin
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on MOH_2017-08-20_000747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-08-20_000747.